Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Retrieved on:
Thursday, December 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ClinicalTrials.gov, Hemoptysis, Proteinuria, Fatal, Recurrence, Hepatocellular carcinoma, Bleeding, Melena, Immunotherapy, PD-L1, Union, Docetaxel, Avascular necrosis, Hypertension, Takeda Pharmaceutical Company, Hematemesis, Fistula, AST, Patient, Pulmonary embolism, ULN, Grade 3, Nivolumab, ONJ, NSCLC, Lung cancer, Venous thrombosis, Sepsis, Post-vaccination embolic and thrombotic events, Roche, Progression-free survival, HIV disease progression rates, Embolism, Nephrotic syndrome, Incidence, ALT, EXEL, VEGFR, Tablet, Survival, History, Sorafenib, DTC, Abscess, HCC, Adrenal insufficiency, Hormone replacement therapy, Perforation, RCC, Ipsen, Risk, Medical imaging, Pharmaceutical industry, Exelixis, Jaw, Takeda
Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
Key Points:
- Exelixis holds the exclusive rights to develop and commercialize cabozantinib in the U.S.
CABOMETYX in combination with atezolizumab is not indicated as a treatment for NSCLC. - The incidence of Grade 3 to 5 hemorrhagic events was 5% in CABOMETYX patients in RCC, HCC, and DTC studies.
- Venous thromboembolism occurred in 7% (including 4% pulmonary embolism) and arterial thromboembolism in 2% of CABOMETYX patients.
- Discontinue CABOMETYX in patients who develop an acute myocardial infarction or serious arterial or venous thromboembolic events that require medical intervention.